{"id":"pegylated-interferon-beta-1a","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Flu-like symptoms"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Headache"},{"rate":"10-30%","effect":"Depression"},{"rate":"10-20%","effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by increasing the production of interferon beta, which helps to reduce inflammation in the central nervous system. This can slow the progression of multiple sclerosis and reduce the frequency of relapses.","oneSentence":"Pegylated interferon beta-1a works by stimulating the body's immune system to fight multiple sclerosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:58.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT02587065","phase":"PHASE4","title":"Plegridy Satisfaction Study in Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-02-03","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS)","enrollment":193},{"nctId":"NCT05242133","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2017-12-20","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":168},{"nctId":"NCT02230969","phase":"","title":"Plegridy Observational Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-11-12","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":1208},{"nctId":"NCT04834401","phase":"","title":"Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis","status":"COMPLETED","sponsor":"St. Barnabas Medical Center","startDate":"2021-03-22","conditions":"Multiple Sclerosis, Covid19","enrollment":45},{"nctId":"NCT04552379","phase":"PHASE3","title":"The Containing Coronavirus Disease 19 (COVID-19) Trial","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-12-01","conditions":"SARS-CoV Infection, Interferon, Covid19","enrollment":1173},{"nctId":"NCT02744222","phase":"PHASE2, PHASE3","title":"Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-08-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":399},{"nctId":"NCT04289675","phase":"","title":"Multiple Sclerosis: Chi3L1 and Treatment Efficacy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2012-01-01","conditions":"Multiple Sclerosis","enrollment":63},{"nctId":"NCT03424733","phase":"PHASE4","title":"Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects","status":"UNKNOWN","sponsor":"Holy Name Medical Center, Inc.","startDate":"2017-09-25","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT02359877","phase":"PHASE1","title":"Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2014-07","conditions":"Healthy","enrollment":60},{"nctId":"NCT01939002","phase":"PHASE3","title":"Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-11","conditions":"Relapsing Multiple Sclerosis","enrollment":251},{"nctId":"NCT01332019","phase":"PHASE3","title":"Long-Term Safety and Efficacy Study of Peginterferon Beta-1a","status":"COMPLETED","sponsor":"Biogen","startDate":"2011-04","conditions":"Relapsing Multiple Sclerosis","enrollment":1077},{"nctId":"NCT02568111","phase":"PHASE4","title":"Brimonidine Tartrate for the Treatment of Injection Related Erythema","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2016-02","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS)","enrollment":""},{"nctId":"NCT02234869","phase":"PHASE4","title":"Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2014-10","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT00906399","phase":"PHASE3","title":"Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-06","conditions":"Relapsing Multiple Sclerosis","enrollment":1516},{"nctId":"NCT01337427","phase":"PHASE3","title":"Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2010-08","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT01119781","phase":"PHASE1","title":"A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-05","conditions":"Healthy, Renal Insufficiency","enrollment":35},{"nctId":"NCT02125578","phase":"PHASE1","title":"A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2008-03","conditions":"Healthy","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pegylated interferon beta-1a","genericName":"Pegylated interferon beta-1a","companyName":"Cinnagen","companyId":"cinnagen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated interferon beta-1a works by stimulating the body's immune system to fight multiple sclerosis. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}